ABIVAX Société Anonyme

Symbol: 0RA9.L

LSE

13.2

EUR

Market price today

  • -4.3146

    P/E Ratio

  • -0.1865

    PEG Ratio

  • 830.51M

    MRK Cap

  • 0.00%

    DIV Yield

ABIVAX Société Anonyme (0RA9-L) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.84%

Operating Profit Margin

-29.38%

Net Profit Margin

-32.88%

Return on Assets

-0.45%

Return on Equity

-1.07%

Return on Capital Employed

-0.51%

Company general description and statistics

Sector: Healthcare
Industry: Medical - Pharmaceuticals
CEO:Mr. Marc M. P. de Garidel M.B.A.
Full-time employees:61
City:Paris
Address:5, rue de la Baume
IPO:2016-09-30
CIK:

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.

General Outlook

When we look at how much money they make before expenses, they keep 0.843% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -29.378%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -32.882%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.452% return, is a testament to ABIVAX Société Anonyme's adeptness in optimizing resource deployment. ABIVAX Société Anonyme's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -1.069%. Furthermore, the proficiency of ABIVAX Société Anonyme in capital utilization is underscored by a remarkable -0.514% return on capital employed.

Stock Prices

ABIVAX Société Anonyme's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $13.34, while its low point bottomed out at $12.92. This variance in figures offers investors a lucid insight into the roller-coaster ride that is ABIVAX Société Anonyme's stock market.

Liquidity Ratios

Analyzing 0RA9.L liquidity ratios reveals its financial health of the firm. The current ratio of 408.29% gauges short-term asset coverage for liabilities. The quick ratio (399.89%) assesses immediate liquidity, while the cash ratio (359.70%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio408.29%
Quick Ratio399.89%
Cash Ratio359.70%

Profitability Ratios

0RA9.L profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -3388.23% underscores its earnings before tax deductions. The effective tax rate stands at 2.95%, revealing its tax efficiency. The net income per EBT, 97.05%, and the EBT per EBIT, 115.33%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -2937.84%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-3388.23%
Effective Tax Rate2.95%
Net Income per EBT97.05%
EBT per EBIT115.33%
EBIT per Revenue-2937.84%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 4.08, it details the span from stock purchase to revenue. The 4 days it takes to settle debts showcases its creditor relations. Meanwhile, a 4 cash conversion cycle and 23.53% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding400
Operating Cycle1551.47
Days of Payables Outstanding11334
Cash Conversion Cycle-9782
Receivables Turnover0.24
Payables Turnover0.03
Inventory Turnover707000.00
Fixed Asset Turnover5.12
Asset Turnover0.01

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -2.07, and free cash flow per share, -2.08, depict cash generation on a per-share basis. The cash per share value, 5.40, showcases liquidity position. Lastly, the operating cash flow sales ratio, -22.26, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-2.07
Free Cash Flow per Share-2.08
Cash per Share5.40
Operating Cash Flow Sales Ratio-22.26
Free Cash Flow to Operating Cash Flow Ratio1.00
Cash Flow Coverage Ratio-1.81
Short Term Coverage Ratio-9.43
Capital Expenditure Coverage Ratio-375.97
Dividend Paid and Capex Coverage Ratio-375.97

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 16.91%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.28, we discern the balance between debt and equity financing. The long-term debt to capitalization, 18.57%, and total debt to capitalization, 22.01%, ratios shed light on its capital structure. An interest coverage of -6.47 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio16.91%
Debt Equity Ratio0.28
Long Term Debt to Capitalization18.57%
Total Debt to Capitalization22.01%
Interest Coverage-6.47
Cash Flow to Debt Ratio-1.81
Company Equity Multiplier1.67

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.10, provides a glimpse into top-line earnings distributed across each share. Net income per share, -3.43, reflects the portion of profit attributed to each share. The book value per share, 4.55, represents the net asset value distributed per share, while the tangible book value per share, 3.97, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share0.10
Net Income Per Share-3.43
Book Value Per Share4.55
Tangible Book Value Per Share3.97
Shareholders Equity Per Share4.55
Interest Debt Per Share1.76
Capex Per Share-0.01

Growth Ratios

EBIT growth, -133.02%, and operating income growth, -133.02%, offer insights into operational profitability progression. The net income growth, -111.04%, showcases bottom-line expansion, and the EPS growth, 24.92%, measures the growth in earnings per share.

cards.indicatorcards.value
Gross Profit Growth100.00%
EBIT Growth-133.02%
Operating Income Growth-133.02%
Net Income Growth-111.04%
EPS Growth24.92%
EPS Diluted Growth-9.58%
Weighted Average Shares Growth-100.00%
Weighted Average Shares Diluted Growth-100.00%
Operating Cash Flow Growth-52.50%
Free Cash Flow Growth-44.18%
5-Year Revenue Growth per Share-100.00%
3-Year Revenue Growth per Share-100.00%
5-Year Operating CF Growth per Share100.00%
3-Year Operating CF Growth per Share100.00%
5-Year Net Income Growth per Share100.00%
3-Year Net Income Growth per Share100.00%
5-Year Shareholders Equity Growth per Share-100.00%
3-Year Shareholders Equity Growth per Share-100.00%
Book Value per Share Growth-100.00%
R&D Expense Growth111.80%
SGA Expenses Growth301.23%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 229,875,518.8, captures the company's total value, considering both debt and equity. Income quality, 0.68, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 4.98, gauges operational efficiency, while the research and development to revenue, 2296.37%, highlights investment in innovation. The ratio of intangibles to total assets, 7.65%, indicates the value of non-physical assets, and capex to operating cash flow, 0.27%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value229,875,518.8
Income Quality0.68
Sales General and Administrative to Revenue4.98
Research and Development to Revenue2296.37%
Intangibles to Total Assets7.65%
Capex to Operating Cash Flow0.27%
Capex to Revenue-5.92%
Capex to Depreciation-37.62%
Stock-Based Compensation to Revenue182.04%
Graham Number18.74
Return on Tangible Assets-48.91%
Graham Net Net3.35
Working Capital215,930,000
Tangible Asset Value170,987,001
Net Current Asset Value154,920,001
Average Receivables13,707,000
Average Payables15,084,499.5
Average Inventory6,093,500.5
Days Sales Outstanding1551
Days Payables Outstanding11334
ROIC-50.97%
ROE-0.75%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 3.25, and the price to book ratio, 3.25, reflect the market's valuation relative to the company's book value. The price to sales ratio, 184.85, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -8.28, and price to operating cash flows, -6.37, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio3.25
Price to Book Ratio3.25
Price to Sales Ratio184.85
Price Cash Flow Ratio-6.37
Price Earnings to Growth Ratio-0.19
Enterprise Value Multiple-7.82
Price Fair Value3.25
Price to Operating Cash Flow Ratio-6.37
Price to Free Cash Flows Ratio-8.28
Price to Tangible Book Ratio2.18
Enterprise Value to Sales51.16
Enterprise Value Over EBITDA-1.75
EV to Operating Cash Flow-2.30
Earnings Yield-34.65%
Free Cash Flow Yield-23.52%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of ABIVAX Société Anonyme (0RA9.L) on the LSE in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -4.315 in 2024.

What is the ticker symbol of ABIVAX Société Anonyme stock?

The ticker symbol of ABIVAX Société Anonyme stock is 0RA9.L.

What is company IPO date?

IPO date of ABIVAX Société Anonyme is 2016-09-30.

What is company current share price?

Current share price is 13.200 EUR.

What is stock market cap today?

The market cap of stock today is 830510485.000.

What is PEG ratio in 2024?

The current -0.187 is -0.187 in 2024.

What is the number of employees in 2024?

In 2024 the company has 61.